Suven Life Sciences’ has said that its clinical candidate SUVN-502 for Alzheimer’s Disease secured several product patents granted at all the key market countries; India (218438), Mexico (257091), South Africa (2005/4043), Singapore (113104), New Zealand (540840), Korea (10-2005-7009512), Eurasia (011320), Australia (2003237599) and Europe (1581492).
Suven has said that SUVN-502 has completed the Phase-I single ascending & multiple ascending studies at Switzerland and demonstrated to be very safe at all doses tested with excellent bioavailability and half life for potential once in a day treatment. Suven is planning to initiate the clinical Phase-II proof-of-concept (POC) studies during 2010. The company targets launching of SUVN-502 in later part of 2013 or early part of 2014. Other molecules in the same category currently in development include GSK’s molecule presently in Phase-II.
Venkat Jasti, CEO, said: “We are very pleased by the grant of these patents at most of the key market countries for our clinical candidate SUVN-502 which is being developed for CNS disorders in the treatment of cognitive impairment, the unmet medical need. Potential market opportunity for these indications is more than $20 billion globally. Granting of these patents to our clinical candidate SUVN-502 is more timely and relevant now that the candidate is ready to enter into Phase-II proof-of-concept (POC) clinical trials during 2010. SUVN-502 attracted lot of scientific and commercial interest from global pharma companies and few companies initiated due diligence process for potential partnering.
Reportedly, the granted product patent for SUVN-502 in all the countries is valid until June 2023.